重大公告
Clarification on the news article by Commercial Times
Date of occurrence of the event: Sept 20, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Date of occurrence of the event: Sept 19, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities
1.Date of the event: Sep 5, 2018 2.Time: 14:30:00 CST 3.Location：Masterlink Securities (Address: No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan) …
OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia
Date of occurrence of the event: Aug 15, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Clarification on the news article by Commercial Times
Date of occurrence of the event: Jul 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …